{"result": "(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Nutrición parenteral is a medical treatment involving the administration of nutrients directly into the bloodstream, often used for patients who cannot eat or absorb food normally.)\n##\n(\"entity\"<|>INSULINA REGULAR<|>ORGANIZATION<|>Insulina regular is a type of insulin used to control blood sugar levels in patients, particularly in the context of parenteral nutrition.)\n##\n(\"entity\"<|>HIPERGLUCEMIA<|>EVENT<|>Hiper glucemia refers to elevated blood sugar levels, which can lead to complications in patients receiving parenteral nutrition.)\n##\n(\"entity\"<|>HIPOGlucemia<|>EVENT<|>Hipoglucemia is a condition characterized by abnormally low blood sugar levels, which can occur in hospitalized patients, especially those on parenteral nutrition.)\n##\n(\"entity\"<|>HIPERTRIGLICERIDEMIA<|>EVENT<|>Hipertrigliceridemia is a condition of elevated triglycerides in the blood, which can be a complication of parenteral nutrition.)\n##\n(\"entity\"<|>PACIENTES<|>PERSON<|>Pacientes refers to individuals receiving medical treatment, particularly those undergoing parenteral nutrition.)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>INSULINA REGULAR<|>Insulina regular is commonly used in conjunction with nutrición parenteral to manage blood glucose levels<|>8)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>HIPERGLUCEMIA<|>Hiper glucemia is a potential complication that can arise from improper management of nutrición parenteral<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>HIPOGlucemia<|>Hipoglucemia can occur in patients receiving nutrición parenteral if insulin management is not properly adjusted<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>HIPERTRIGLICERIDEMIA<|>Hipertrigliceridemia can be a complication of nutrición parenteral if lipid administration is not monitored<|>6)\n##\n(\"relationship\"<|>PACIENTES<|>NUTRICIÓN PARENTERAL<|>Pacientes are the individuals receiving nutrición parenteral treatment<|>9)\n##\n(\"relationship\"<|>PACIENTES<|>HIPERGLUCEMIA<|>Pacientes receiving nutrición parenteral are at risk of developing hiper glucemia<|>8)\n##\n(\"relationship\"<|>PACIENTES<|>HIPOGlucemia<|>Pacientes can experience hipoglucemia, especially if insulin doses are not properly managed<|>8)\n##\n(\"relationship\"<|>PACIENTES<|>HIPERTRIGLICERIDEMIA<|>Pacientes on nutrición parenteral may develop hipertrigliceridemia if lipid levels are not monitored<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ando los niveles de glucosa son superiores a 180 mg/dl, se altera la función inmune, aumenta el riesgo de complicaciones infecciosas y la mortalidad en pacientes con NP⁵⁸⁻⁶⁰.\n\n- Manejo de la hiperglucemia:\n\nSe recomiendan controles de glucemia capilar cada 6-8 horas, y valorar la necesidad de administración de insulina para conseguir objetivos glucémicos (140-180 mg/dl)⁶¹.\n\nLa administración recomendada de insulina, puede ser subcutánea (insulina basal), endovenosa (independiente a la NP) o dentro de la bolsa de NP. No existen estudios aleatorizados que comparen las diferentes formas de administración de la insulina, pero con todos ellos se pueden lograr niveles de glucemia adecuados.\n\nLa utilización de insulina regular añadida a la bolsa de nutrición parenteral es habitual en la práctica clínica y permite un correcto control metabólico. Además,\n\n| Tabla 5. Complicaciones de la nutrición parenteral. |\n|---------------------------------------------------|\n| Complicaciones metabólicas:                        |\n| · Síndrome de realimentación                       |\n| · Hiperglucemia                                    |\n| · Hipoglucemia                                     |\n| · Hipertrigliceridemia                             |\n| Déficit o exceso de micronutrientes                |\n| Alteraciones hepatobiliares                        |\n| Enfermedad metabólica ósea                         |\n| Complicaciones por catéter                         |\n---\nTema 48. Nutrición parenteral       771\n\ncon el uso de insulina regular dentro de la bolsa de NP, el riesgo de hipoglucemia es escaso cuando se suspen- de la NP, ya que simultáneamente se suspende el apor- te de insulina56, 62. La administración de insulina regular dentro de la bolsa de NP se puede iniciar según diver- sos protocolos, como son:\n\n- Administrando en la bolsa de NP el 50-66% de lo necesitado como insulina subcutánea el día previo, con ajuste posterior en función de las glucemias capilares62.\n- Con la administración de 0,05-0,1 UI de insuli- na regular /g de glucosa en la bolsa de NP en pacientes con hiperglucemia de estrés62 o con 0,15-0,25 UI de insulina regular/g de glucosa en pacientes con diabetes previa o tratamiento con glucocorticoides61.\n\n### 7.1.3. Hipoglucemia\n\nLa hipoglucemia en el paciente hospitalizado, se re- fiere a niveles de glucemia menores de 70 mg/dl55. La prevalencia descrita de hipoglucemia en los pacientes con NP es del 4-40%; esta variabilidad depende del tipo de paciente estudiado y del valor que determina la hipoglucemia. En un estudio multicéntrico reciente, la prevalencia observada en pacientes no críticos fue del 6,8%63.\n\nAlgunos estudios retrospectivos han demostrado cómo la presencia de hipoglucemias severas (< 40 mg/ dl), en pacientes críticos, tienen un incremento signifi- cativo de la morbimortalidad55. Otros estudios más re- cientes también relacionan la presencia de hipogluce- mias leves o moderadas (40-70 mg/dl) en pacientes críticos, con un incremento de la mortalidad64. Ade- más, en estos pacientes, los síntomas de hipoglucemia leve-moderada pueden no ser evidentes por bajo nivel de conciencia o sedación55.\n\n• Manejo de la hipoglucemia:\n\nSe recomienda reducir la dosis de insulina en un 50%, si las glucemias capilares son menores de 70 mg/ dl. Aunque es muy poco frecuente, se han descrito hi- poglucemias de rebote después de retirar la NP funda- mentalmente en pacientes que reciben dosis altas de insulina. Para evitarlo, se recomienda reducir el ritmo de infusión de la NP al 50% en las 2 horas previas a su interrupción.\n\n### 7.1.4. Hipertrigliceridemia\n\nLa administración de lípidos no debería exceder su capacidad de aclaramiento plasmático, siendo la con- centración de triglicéridos en plasma el método para valorarla. Si la determinación se realiza más de 6 horas después de terminada la infusión lipídica, se conside- ran aceptables valores hasta de 200 mg/dl y hasta de 400 mg/dl si la extracción se realiza durante la infu-\n\nsión. Si las concentraciones plasmáticas exceden di- chos valores, se debe considerar la reducción en la can- tidad de lípidos administrados, e incluso modificar el tipo de emulsión lipídico hacia aquellas con más rápido aclaramiento (TCM).\n\n• Manejo de la hipertrigliceridemia38:\n  - Determinación de triglicéridos al inicio y tras 24 horas del inicio de\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}